PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1997 | 1 |
| 1998 | 1 |
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 3 |
| 2002 | 5 |
| 2003 | 5 |
| 2004 | 8 |
| 2005 | 7 |
| 2006 | 15 |
| 2007 | 20 |
| 2008 | 42 |
| 2009 | 58 |
| 2010 | 66 |
| 2011 | 74 |
| 2012 | 49 |
| 2013 | 36 |
| 2014 | 55 |
| 2015 | 42 |
| 2016 | 41 |
| 2017 | 31 |
| 2018 | 16 |
| 2019 | 16 |
| 2020 | 32 |
| 2021 | 63 |
| 2022 | 35 |
| 2023 | 28 |
| 2024 | 40 |
| 2025 | 44 |
| 2026 | 28 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Gene Ther"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
FMR1 gene therapy restores translationally relevant phenotypes in a mouse model for fragile X syndrome.
- Lacher RK, Henson K, Wathen LN, Jones C, Arnold T, Rice MR, Carles HM, White AR, Ramsuchit E, Murrey D, Raig R, Fisher A, Bucher K, Westerkamp GC, Fritz AL, Gollaway BM, Piloto S, Dismuke D, Robinson JE, Williams MT, Vorhees CV, De Silva EK, Tiwari D, Erickson CA, Pedapati EV, Gross C.
- Gene Ther. 2026 Jul 10;33(5):515-531. doi: 10.1038/s41434-026-00630-4.
- PMCID: PMC13585560
Lacher RK, et al.Gene Ther. 2026.PMCID: PMC13585560 -
High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.
- Dennett P, Young LM, Draper BE, Schmitt J, Jarrold M, Perez-Lorenzo LJ.
- Gene Ther. 2026 Jun 4;33(5):609-615. doi: 10.1038/s41434-026-00626-0.
- PMCID: PMC13585554
Dennett P, et al.Gene Ther. 2026.PMCID: PMC13585554 -
Characterization of CAR-T cell factors that contribute to myeloid cell activation.
- Khanal S, Hossain MK, Fischer J, Panthi S, Baer A, Bhattarai N.
- Gene Ther. 2026 May 26;33(5):616-627. doi: 10.1038/s41434-026-00620-6.
- PMCID: PMC13585559
Khanal S, et al.Gene Ther. 2026.PMCID: PMC13585559 -
AAV2 capsid clearance and neuronal trafficking dynamics in the central nervous system.
- Gullapalli T, Willows JW, Karkhah A, Munjal V, Nimmo A, Ceyhan KE, Travis M, O'Brien A, Rocco MT, Taunque AS, Townsend KL, Samaranch L.
- Gene Ther. 2026 Apr 30;33(5):628-634. doi: 10.1038/s41434-026-00617-1.
- PMCID: PMC13585552
Gullapalli T, et al.Gene Ther. 2026.PMCID: PMC13585552 -
Correction: Genetic mutations in HSV-1 replication-defective vectors: Implications for their safety in gene therapy applications.
- Cattaneo S, Bettegazzi B, Ingusci S, Verlengia G, Tascini AS, Zucchini S, Codazzi F, Morelli MJ, Marzulli M, Glorioso JC, Simonato M.
- Gene Ther. 2026 Sep;33(5):644. doi: 10.1038/s41434-026-00615-3.
- PMCID: PMC13585558
Cattaneo S, et al.Gene Ther. 2026.PMCID: PMC13585558 -
Beneficial bystander-enhanced cryptic splice rescue of cardiac-type Fabry GLA IVS4+919G>A by adenine base editing in patient fibroblasts.
- Chao HC, Lu YY, Chiang YT, Chen YR, Yen CT, Huang CY, Chang SK, Cheng YF, Lu YH, Niu DM.
- Gene Ther. 2026 Apr 18;33(5):532-540. doi: 10.1038/s41434-026-00612-6.
- PMCID: PMC13585561
Chao HC, et al.Gene Ther. 2026.PMCID: PMC13585561 -
In vitro and in vivo rescue of dopaminergic neurons in Parkinson's disease models after Parkin gene therapy.
- Hioki T, Nishimura M, Sun X, Jacobo SM, Nakayama M, Nishihara M, Tohyama K, Liu PT, Okai T, Tanaka M, Proetzel G.
- Gene Ther. 2026 Mar 5;33(4):448-461. doi: 10.1038/s41434-026-00599-0.
- PMCID: PMC13472879
Hioki T, et al.Gene Ther. 2026.PMCID: PMC13472879 -
Virus-mediated gene transfer of soluble amyloid precursor protein-alpha via systemic injection in a mouse model of Alzheimer's disease.
- He Y, Mockett BG, Schoderboeck L, McDonald KO, Logan BJ, Sateesh S, Jones OD, Hughes SM, Abraham WC.
- Gene Ther. 2026 Mar 3;33(4):474-485. doi: 10.1038/s41434-026-00602-8.
- PMCID: PMC13473021
He Y, et al.Gene Ther. 2026.PMCID: PMC13473021 -
AAV-based gene therapies for neovascular AMD.
- Kim TH, Kwon CY, Song JY, Yoo HC.
- Gene Ther. 2026 Feb 13;33(4):383-397. doi: 10.1038/s41434-026-00595-4.
- PMCID: PMC13473015
Kim TH, et al.Gene Ther. 2026.PMCID: PMC13473015 -
AAV-mediated BDNF and GAS6 muscle delivery delays disease onset in SOD1G93A ALS mice.
- Le Y, Liu G, Wu S, Nissenbaum M, Kusnecov AW, Furmanski P, Birge RB, Zhou R.
- Gene Ther. 2025 Nov 13;33(4):462-473. doi: 10.1038/s41434-025-00577-y.
- PMCID: PMC13472854
Le Y, et al.Gene Ther. 2025.PMCID: PMC13472854